● Recruiting

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Condition: Advanced Solid Tumors · Sponsor: Eikon Therapeutics

PhasePhase 1/Phase 2

Planned participants130

Who can joinAll sexes, 18 Years to 89 Years

Healthy volunteersNo

About this study

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

This description comes directly from the study's public registry record.

Talk to the study team

Sunny Chaudry, MS · 6319026200 · chaudrys@eikontx.com

Always discuss trial participation with your own doctor first.

Locations (10)

Sarah Cannon Research Institute at HealthOne	Denver, Colorado, United States	Recruiting
Florida Cancer Center	Lake Mary, Florida, United States	Recruiting
Beth Israel Deaconess Medical Center	Boston, Massachusetts, United States	Recruiting
MD Anderson	Houston, Texas, United States	Recruiting
NEXT Oncology	San Antonio, Texas, United States	Recruiting
NEXT Virginia	Fairfax, Virginia, United States	Recruiting
PASO Medical	Frankston, Victoria, Australia	Recruiting
Chongqing University Cancer Hospital	Chongqing, Chongqing Municipality, China	Recruiting
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)	Jinan, Shandong, China	Recruiting
Fudan University Shanghai Cancer Center	Shanghai, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06907043